WHO South-East Asia Commits to Accelerated Action on TB

At the 79th Session of the Regional Committee, Member States reinforced their commitment to tackle Tuberculosis in South-East Asia. Specifically, health ministers gathered in Dili to resolve ongoing gaps across screening, prevention, and therapy. In addition, delegates prioritized measures to insulate vulnerable families from catastrophic financial distress. Dr Nilesh Buddha emphasized that modern medicine already provides proven tools to alter disease trajectories. Therefore, regional health systems must deliver these interventions equitably through strong primary care networks.

Epidemiological Burden of Tuberculosis in South-East Asia

The South-East Asia region remains disproportionately impacted by the global tuberculosis pandemic. In 2024, the region accounted for approximately 34 percent of all new global TB diagnoses. Specifically, this total represented an estimated 3.68 million active cases alongside 433,000 avoidable deaths. Furthermore, drug-resistant pathogens present severe clinical challenges throughout member nations. Approximately 150,000 individuals developed multidrug-resistant or rifampicin-resistant TB during that same period. Notably, this statistic constitutes more than 38 percent of the entire worldwide drug-resistant caseload.

Strengthening Early Detection and Molecular Diagnostics

To reverse these trends, countries agreed to intensify complete case detection across clinical networks. Health authorities will deploy systematic screening protocols and targeted active case finding within vulnerable communities. Additionally, clinicians will expand the routine use of WHO-recommended rapid molecular diagnostic platforms. Digital diagnostic tools and automated chest radiography will further improve case notification accuracy. Consequently, practitioners can identify asymptomatic or early-stage pulmonary infections before community transmission escalates. Moreover, early bacteriological confirmation prevents inappropriate empiric regimens that promote antimicrobial resistance.

People-Centred Care and Preventive Therapeutics

Member States also resolved to reconstruct regional care models around the holistic needs of patients. For instance, program guidelines now emphasize integrated social support, nutritional supplementation, and continuous community counselling. Healthcare leaders must proactively dismantle social stigma, administrative barriers, and geographical disparities in treatment delivery. Simultaneously, health systems will expand TB preventive treatment to eligible household contacts and high-risk groups. Clinicians will also aggressively manage comorbidities that amplify tuberculosis risks, including undernutrition, diabetes mellitus, and tobacco dependence. As a result, comprehensive infection control and targeted chemoprophylaxis will interrupt transmission pathways.

Overcoming Financial Hardship and Funding Deficits

Catastrophic health expenditure remains one of the largest impediments to ending TB across Asia. Presently, nearly 44 percent of TB-affected families endure ruinous out-of-pocket costs during treatment. Specifically, for drug-resistant tuberculosis cases, this alarming figure exceeds 80 percent of affected households. Furthermore, an acute funding gap threatens regional public health interventions. In 2024, available funding reached only 900 million dollars against an estimated requirement of 3 billion dollars. Therefore, delegates urged governments to integrate tuberculosis management into universal health coverage financing schemes.

The Potential Impact of Future Tuberculosis Vaccines

Between 2015 and 2024, the region lowered TB incidence by 16 percent and mortality by 23 percent. In addition, national treatment success rates consistently surpassed 85 percent across participating territories. Nevertheless, these substantial improvements fall short of the End TB Strategy targets for 2030. To bridge this critical shortfall, regional epidemiological models underscore the necessity of novel vaccines. In fact, deploying an effective TB vaccine by 2028 alongside current clinical strategies could avert 1.45 million new cases. Thus, such an innovation could prevent 300,000 related deaths across South-East Asia before 2030.

Frequently Asked Questions

Q1: What are the main commitments made at the 79th Session of the WHO Regional Committee?

Member States committed to expanding rapid molecular diagnostics, reinforcing active case finding, and ensuring universal access to preventive therapy. Furthermore, countries pledged to eliminate financial burdens for affected households and prepare health systems for new vaccines.

Q2: Why are new tuberculosis vaccines considered essential for South-East Asia?

Current diagnostic and therapeutic measures alone cannot meet the 2030 End TB Strategy reduction targets. However, introducing a new TB vaccine by 2028 could avert approximately 1.45 million cases and 300,000 deaths by 2030.

Q3: How severe is the financial burden on tuberculosis patients in the region?

Nearly 44 percent of all TB-affected households experience catastrophic costs during illness. Moreover, this financial hardship rises to over 80 percent among families managing drug-resistant tuberculosis.

References

1. WHO South-East Asia Region commits to stronger action to end Tuberculosis - ETHealthworld
2. Closing the Gap to End TB: Strategic Priorities for the WHO South-East Asia Region - World Health Organization
3. Ending TB in South-East Asia: flagship priority and response transformation - PMC